Northern Capital Management Has Trimmed Its Lear (LEA) Position; Profile of 8 Analysts Covering Arena Pharmaceuticals, Inc. (ARNA)

June 5, 2018 - By Ellis Scott

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Logo

Among 10 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Arena Pharmaceuticals had 27 analyst reports since October 28, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating on Wednesday, July 19. Cantor Fitzgerald has “Buy” rating and $3700 target. The stock has “Buy” rating by Cantor Fitzgerald on Monday, February 26. The company was maintained on Wednesday, April 18 by Cantor Fitzgerald. The firm earned “Buy” rating on Thursday, June 29 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, May 9. Wells Fargo upgraded Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Wednesday, January 3 to “Outperform” rating. Cantor Fitzgerald maintained the shares of ARNA in report on Tuesday, July 11 with “Buy” rating. The rating was maintained by Cantor Fitzgerald on Tuesday, March 20 with “Buy”. The firm has “Outperform” rating given on Thursday, September 15 by FBR Capital. Leerink Swann maintained the shares of ARNA in report on Wednesday, January 17 with “Buy” rating. See Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) latest ratings:

09/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $65.0000 Maintain
18/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $65.0000 Maintain
21/03/2018 Broker: Citigroup Rating: Buy New Target: $62.0
20/03/2018 Broker: Wells Fargo Rating: Buy New Target: $60.0 Maintain
20/03/2018 Broker: J.P. Morgan Rating: Hold New Target: $48.0
20/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $64.0 Maintain
20/03/2018 Broker: Needham Old Rating: Hold New Rating: Buy Upgrade
14/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $45.0 Maintain
26/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $45.0 Maintain
27/02/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $37 New Target: $55 Maintain

Northern Capital Management Llc decreased Lear Corp (LEA) stake by 87.81% reported in 2018Q1 SEC filing. Northern Capital Management Llc sold 11,420 shares as Lear Corp (LEA)’s stock rose 2.38%. The Northern Capital Management Llc holds 1,585 shares with $295,000 value, down from 13,005 last quarter. Lear Corp now has $13.30B valuation. The stock decreased 0.45% or $0.91 during the last trading session, reaching $200.54. About 537,675 shares traded. Lear Corporation (NYSE:LEA) has risen 37.02% since June 5, 2017 and is uptrending. It has outperformed by 24.45% the S&P500. Some Historical LEA News: ; 26/04/2018 – LEAR CORP SEES FULL YEAR 2018 PRETAX OPERATIONAL RESTRUCTURING COSTS ARE ESTIMATED TO BE $70 MLN; 22/03/2018 – LEAR CORP LEA.N : MORGAN STANLEY RAISES TO EQUAL-WEIGHT FROM UNDERWEIGHT; 21/03/2018 – LEAR EXPANDS SEATING STRUCTURES PLANT IN VALENÇA, PORTUGAL; 04/04/2018 – WJRT-TV: Lear Corp. employees volunteer time at Catholic Charities of Flint; 27/04/2018 – Lear Corporation Recognized by General Motors as “Supplier of the Year for Complete Seat”; 06/04/2018 – INTERNATIONAL AUTOMOTIVE COMPONENTS SAYS WL ROSS AND FRANKLIN MUTUAL ADVISERS WILL REMAIN CO’S MAJORITY SHAREHOLDERS; 24/05/2018 – U.S. auto import probe fans tariff fears, riles Asia, Europe carmakers; 26/04/2018 – LEAR CORP LEA.N SEES FY 2018 SALES $21.8 BLN TO $22 BLN; 26/04/2018 – LEAR CORP SEES FULL YEAR 2018 CAPITAL EXPENDITURES ARE EXPECTED TO BE $660 MLN, AND DEPRECIATION AND AMORTIZATION EXPENSE IS ESTIMATED TO BE $500 MLN; 23/04/2018 – DJ Lear Corporation, Inst Holders, 1Q 2018 (LEA)

Investors sentiment decreased to 0.93 in Q1 2018. Its down 0.03, from 0.96 in 2017Q4. It dropped, as 23 investors sold LEA shares while 193 reduced holdings. 64 funds opened positions while 136 raised stakes. 55.69 million shares or 4.05% less from 58.04 million shares in 2017Q4 were reported. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Management Corporation stated it has 0.44% in Lear Corporation (NYSE:LEA). Moreover, Carroll Associate Inc has 0% invested in Lear Corporation (NYSE:LEA). Stifel Financial has invested 0.03% in Lear Corporation (NYSE:LEA). Guggenheim Cap Limited Liability Corporation, Illinois-based fund reported 86,943 shares. Wesbanco Bancorporation accumulated 30,315 shares. Gotham Asset Management Limited Liability Corp invested in 46,962 shares or 0.12% of the stock. Sumitomo Mitsui Asset Management Com, a Japan-based fund reported 4,396 shares. Riverhead Capital Management Ltd Liability accumulated 43,000 shares. 189,572 are owned by Citigroup Inc. Arizona State Retirement Sys has invested 0.05% in Lear Corporation (NYSE:LEA). Koch Inc holds 0.12% or 6,473 shares. Bancorporation Of Montreal Can stated it has 1.62 million shares or 0.27% of all its holdings. Jennison Associates Limited Liability Corp stated it has 10,980 shares. Nomura Hldg stated it has 0.03% of its portfolio in Lear Corporation (NYSE:LEA). Cibc Asset Incorporated reported 3,058 shares or 0% of all its holdings.

Among 21 analysts covering Lear Corporation (NYSE:LEA), 12 have Buy rating, 1 Sell and 8 Hold. Therefore 57% are positive. Lear Corporation had 80 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Lear Corporation (NYSE:LEA) earned “Equal Weight” rating by Barclays Capital on Monday, January 25. As per Monday, October 16, the company rating was maintained by RBC Capital Markets. Citigroup maintained the stock with “Buy” rating in Tuesday, August 2 report. Deutsche Bank upgraded the stock to “Buy” rating in Monday, July 27 report. RBC Capital Markets maintained the shares of LEA in report on Tuesday, December 19 with “Buy” rating. The rating was downgraded by Zacks on Tuesday, August 25 to “Buy”. The stock has “Buy” rating by UBS on Tuesday, August 18. On Friday, October 20 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The firm earned “Buy” rating on Tuesday, April 17 by Robert W. Baird. The firm has “Neutral” rating by Guggenheim given on Thursday, October 26.

Northern Capital Management Llc increased Liberty Global Cl C (NASDAQ:LBTYK) stake by 10,910 shares to 58,327 valued at $1.78 million in 2018Q1. It also upped Apple Computer Inc (NASDAQ:AAPL) stake by 3,298 shares and now owns 54,812 shares. Allergan Inc was raised too.

Since February 16, 2018, it had 0 insider buys, and 13 insider sales for $47.12 million activity. 5,373 Lear Corporation (NYSE:LEA) shares with value of $1.02M were sold by BURGESS SHARI L. Kunkel Jay K. had sold 6,694 shares worth $1.27M on Friday, February 16. $4.07M worth of Lear Corporation (NYSE:LEA) was sold by DiDonato Thomas A on Friday, February 16. On Friday, February 16 Orsini Frank C sold $4.13M worth of Lear Corporation (NYSE:LEA) or 21,706 shares. $360,537 worth of Lear Corporation (NYSE:LEA) was sold by SMITH GREG C on Thursday, May 17. Simoncini Matthew sold $19.01 million worth of stock. SCOTT RAYMOND E had sold 25,545 shares worth $4.86M on Friday, February 16.

More notable recent Lear Corporation (NYSE:LEA) news were published by: Streetinsider.com which released: “Lear Corp. (LEA) Names John Absmeier as CTO” on June 05, 2018, also Prnewswire.com with their article: “Lear Hires John Absmeier as Chief Technology Officer” published on June 05, 2018, Seekingalpha.com published: “Lear Corporation: Primed For A Breakout” on May 17, 2018. More interesting news about Lear Corporation (NYSE:LEA) were released by: Prnewswire.com and their article: “Ford Honors Lear Corporation at 20th Annual World Excellence Awards” published on May 30, 2018 as well as Streetinsider.com‘s news article titled: “Paulson’s 13F Shows New Stake in Goldcorp (GG), Increase in Discovery (DISCA), Viacom (VIAB) (more…)” with publication date: May 15, 2018.

Analysts await Lear Corporation (NYSE:LEA) to report earnings on July, 25. They expect $5.03 EPS, up 14.58% or $0.64 from last year’s $4.39 per share. LEA’s profit will be $333.59 million for 9.97 P/E if the $5.03 EPS becomes a reality. After $5.10 actual EPS reported by Lear Corporation for the previous quarter, Wall Street now forecasts -1.37% negative EPS growth.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $2.38 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

More notable recent Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 31, 2018, also Seekingalpha.com with their article: “Arena Pharmaceuticals’ (ARNA) CEO Amit Munshi presents at Bank of America Merrill Lynch Healthcare Brokers …” published on May 18, 2018, Seekingalpha.com published: “Arena Pharmaceuticals’ (ARNA) CEO Presents at UBS Global Healthcare Brokers Conference (Transcript)” on May 22, 2018. More interesting news about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) were released by: Seekingalpha.com and their article: “Arena Pharmaceuticals’ (ARNA) CEO Amit Munshi on Q1 2018 Results – Earnings Call Transcript” published on May 15, 2018 as well as Streetinsider.com‘s news article titled: “RBC Capital Starts Arena Pharma (ARNA) at Outperform” with publication date: May 31, 2018.

The stock decreased 1.00% or $0.49 during the last trading session, reaching $48.37. About 521,942 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has risen 233.31% since June 5, 2017 and is uptrending. It has outperformed by 220.74% the S&P500. Some Historical ARNA News: ; 19/03/2018 – Arena Pharma: Safety Results Support Potential Best-In-Class Profile; 19/03/2018 – Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis; 19/03/2018 – ARENA PHARMACEUTICALS REPORTS POSITIVE PHASE 2 RESULTS FOR THE OASIS TRIAL FOR ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS; 22/05/2018 – Arena Pharma at American Thoracic Society Meeting Tomorrow; 19/03/2018 – ARENA PHARMACEUTICALS – ETRASIMOD WAS WELL TOLERATED, HAD FEWER PATIENTS WITH SERIOUS ADVERSE EVENTS VS PLACEBO IN STUDY; 19/03/2018 – Arena Pharma: OASIS Trial Met Endpoints With Statistical Significance With 2 Mg Dose of Etrasimod for 12 Weeks; 26/03/2018 – Arena Pharmaceuticals Announces Completion of Public Offering of Common Stk and Exercise in Full of Underwriters’ Option to Purchase Additional Shrs; 19/03/2018 – Arena Pharmaceuticals: OASIS Trial Met Primary and All Secondary Endpoints; 14/03/2018 – Arena Pharmaceuticals Etrasimod Phase 2 Data in UC Anticipated This Mo; 19/03/2018 – ARENA – IMPACT ON HEART RATE, ATRIOVENTRICULAR (AV) CONDUCTION LOW IN STUDY WITH NO DISCONTINUATIONS RELATED TO BRADYCARDIA OR AV BLOCK

Lear Corporation (NYSE:LEA) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>